Related Experiment Video
Updated: Jun 24, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy
Jochen Tuettenberg1, Rainer Grobholz, Marcel Seiz
1Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg, 68167 Mannheim, Germany. jochen.tuettenberg@nch.ma.uni-heidelberg.de
Purpose:
Glioblastoma multiforme is the prototype of an angiogenic tumour. Under experimental conditions, anti-angiogenic therapy strategies lead to an increased invasion. Here we report on the pattern of tumour recurrence in glioblastoma patients treated with an anti-angiogenic chemotherapy.
Patients And Methods:
A total of 32 patients with glioblastoma multiforme and a residual tumour mass after operation were treated with a continuous low-dose chemotherapy with temozolomide and a COX-II inhibitor, a presumably anti-angiogenic therapy.
Results:
While anti-tumour activity of this therapy regimen was excellent with a mean overall time to progression of 10.4 (+/-0.9) months and a mean overall survival of 17.8 (+/-1.5) months, an unusually high rate of distant recurrences was observed (62.5%).
Conclusion:
Patients treated with an anti-angiogenic chemotherapy experience distant recurrences at a higher rate than reported for conventional therapies. This may reflect an anti-angiogenic therapy-induced activation of glioma invasion confirming similar recently published experimental results.
